Influence of Disease Type and Activity on Adalimumab Exposure in Children with Inflammatory Rheumatic Diseases

Keyphrases

• Adalimumab 100%
• Disease Pattern 100%
• Disease Activity 100%
• Inflammatory Rheumatic Diseases 100%
• Pediatric 64%
• Disease-specific 29%
• Specific Factors 29%
• Systemic Juvenile Idiopathic Arthritis (sJIA) 17%
• Idiopathic Uveitis 17%
• Pharmacokinetics 11%
• Methotrexate 11%
• Inter-individual Variability 11%
• One-compartment Model 11%
• Allometric Scaling 11%
• Inactive Disease 11%
• Dose Individualization 11%
• Tumor Necrosis Factor-α 5%
• Remission 5%
• Dose Escalation 5%
• Monoclonal Antibody 5%
• Drug Exposure 5%
• Steady State 5%
• Clinical Practice 5%
• Active Disease 5%
• Nave 5%
• First Dose 5%
• Prospective Clinical Study 5%
• First-order 5%
• Clinical Research 5%
• Dosing Strategy 5%
• Inflammatory Diseases 5%
• Drug Response 5%
• Overexposure 5%
• Pediatric Research 5%
• Pediatric Rheumatology 5%
• Idiopathic Disease 5%
• Weight-based 5%
• Two-center 5%
• Personalized Treatment 5%
• Exposure-response 5%
• Prolonged Duration 5%
• Individualized Treatment 5%
• Pharmacokinetic Data 5%
• Therapeutic Drug Monitoring 5%
• Research Policy 5%
• Underexposure 5%
• Pharmacometrics 5%
• Personalized Dosing 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Adalimumab 100%
• Rheumatic Disease 100%
• Diseases 100%
• Uveitis 17%
• Juvenile Rheumatoid Arthritis 17%
• Pharmacokinetics 17%
• Methotrexate 11%
• Disease Activity 11%
• Tumor Necrosis Factor 5%
• Prospective Study 5%
• Clinical Study 5%
• Remission 5%
• Monoclonal Antibody 5%
• Elimination 5%
• Clinical Research 5%
• Therapeutic Drug Monitoring 5%
• Inflammatory Disease 5%
• Pharmacometrics 5%

Immunology and Microbiology

• Rheumatic Disease 100%
• Adalimumab 100%
• Juvenile Idiopathic Arthritis 17%
• Uveitis 17%
• Pharmacokinetics 17%
• Methotrexate 11%
• Monoclonal Antibody 5%
• Drug Exposure 5%
• Inflammatory Disorder 5%
• Absorption 5%
• Steady State 5%
• Tumor Necrosis Factor Alpha 5%
• Drug Response 5%